[{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"}]